1
|
Katiraei S, de Vries MR, Costain AH, Thiem K, Hoving LR, van Diepen JA, Smits HH, Bouter KE, Rensen PCN, Quax PHA, Nieuwdorp M, Netea MG, de Vos WM, Cani PD, Belzer C, van Dijk KW, Berbée JFP, van Harmelen V. Akkermansia muciniphila Exerts Lipid-Lowering and Immunomodulatory Effects without Affecting Neointima Formation in Hyperlipidemic APOE*3-Leiden.CETP Mice. Mol Nutr Food Res 2020; 64:e1900732. [PMID: 31389129 PMCID: PMC7507188 DOI: 10.1002/mnfr.201900732] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Indexed: 12/21/2022]
Abstract
SCOPE Akkermansia muciniphila (A. muciniphila) is an intestinal commensal with anti-inflammatory properties both in the intestine and other organs. The aim is to investigate the effects of oral administration of A. muciniphila on lipid metabolism, immunity, and cuff-induced neointima formation in hyperlipidemic APOE*3-Leiden (E3L).CETP mice. METHODS AND RESULTS Hyperlipidemic male E3L.CETP mice are daily treated with 2 × 108 CFU A. muciniphila by oral gavage for 4 weeks and the effects are determined on plasma lipid levels, immune parameters, and cuff-induced neointima formation and composition. A. muciniphila administration lowers body weight and plasma total cholesterol and triglycerides levels. A. muciniphila influences the immune cell composition in mesenteric lymph nodes, as evident from an increased total B cell population, while reducing the total T cell and neutrophil populations. Importantly, A. muciniphila reduces the expression of the activation markers MHCII on dendritic cells and CD86 on B cells. A. muciniphila also increases whole blood ex vivo lipopolysaccharide-stimulated IL-10 release. Finally, although treatment with A. muciniphila improves lipid metabolism and immunity, it does not affect neointima formation or composition. CONCLUSIONS Four weeks of treatment with A. muciniphila exerts lipid-lowering and immunomodulatory effects, which are insufficient to inhibit neointima formation in hyperlipidemic E3L.CETP mice.
Collapse
Affiliation(s)
- Saeed Katiraei
- Department of Human GeneticsLeiden University Medical Center2300 RCLeidenThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Margreet R. de Vries
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
- Department of SurgeryLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Alice H. Costain
- Department of ParasitologyLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Kathrin Thiem
- Department of Internal MedicineRadboud UMC6525 GANijmegenThe Netherlands
| | - Lisa R. Hoving
- Department of Human GeneticsLeiden University Medical Center2300 RCLeidenThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
| | | | - Hermelijn H. Smits
- Department of ParasitologyLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Kristien E. Bouter
- Department of Vascular MedicineAcademic Medical Center1105 AZAmsterdamThe Netherlands
| | - Patrick C. N. Rensen
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
- Department of Medicinedivision of EndocrinologyLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Paul H. A. Quax
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
- Department of SurgeryLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Max Nieuwdorp
- Department of Vascular MedicineAcademic Medical Center1105 AZAmsterdamThe Netherlands
| | - Mihai G. Netea
- Department of Internal MedicineRadboud UMC6525 GANijmegenThe Netherlands
| | - Willem M. de Vos
- Laboratory of MicrobiologyWageningen University6708 WEWageningenThe Netherlands
| | - Patrice D. Cani
- Université catholique de LouvainLouvain Drug Research InstituteWELBIO (Walloon Excellence in Life sciences and BIOtechnology)Metabolism and Nutrition Research Group1200BrusselsBelgium
| | - Clara Belzer
- Laboratory of MicrobiologyWageningen University6708 WEWageningenThe Netherlands
| | - Ko Willems van Dijk
- Department of Human GeneticsLeiden University Medical Center2300 RCLeidenThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
- Department of Medicinedivision of EndocrinologyLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Jimmy F. P. Berbée
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
- Department of Medicinedivision of EndocrinologyLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Vanessa van Harmelen
- Department of Human GeneticsLeiden University Medical Center2300 RCLeidenThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
| |
Collapse
|
2
|
Deschasaux M, Bouter KE, Prodan A, Levin E, Groen AK, Herrema H, Tremaroli V, Bakker GJ, Attaye I, Pinto-Sietsma SJ, van Raalte DH, Snijder MB, Nicolaou M, Peters R, Zwinderman AH, Bäckhed F, Nieuwdorp M. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat Med 2018; 24:1526-1531. [DOI: 10.1038/s41591-018-0160-1] [Citation(s) in RCA: 304] [Impact Index Per Article: 50.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 07/23/2018] [Indexed: 12/16/2022]
|
3
|
Udayappan SD, Kovatcheva-Datchary P, Bakker GJ, Havik SR, Herrema H, Cani PD, Bouter KE, Belzer C, Witjes JJ, Vrieze A, de Sonnaville N, Chaplin A, van Raalte DH, Aalvink S, Dallinga-Thie GM, Heilig HGHJ, Bergström G, van der Meij S, van Wagensveld BA, Hoekstra JBL, Holleman F, Stroes ESG, Groen AK, Bäckhed F, de Vos WM, Nieuwdorp M. Intestinal Ralstonia pickettii augments glucose intolerance in obesity. PLoS One 2017; 12:e0181693. [PMID: 29166392 PMCID: PMC5699813 DOI: 10.1371/journal.pone.0181693] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Accepted: 07/04/2017] [Indexed: 01/07/2023] Open
Abstract
An altered intestinal microbiota composition has been implicated in the pathogenesis of metabolic disease including obesity and type 2 diabetes mellitus (T2DM). Low grade inflammation, potentially initiated by the intestinal microbiota, has been suggested to be a driving force in the development of insulin resistance in obesity. Here, we report that bacterial DNA is present in mesenteric adipose tissue of obese but otherwise healthy human subjects. Pyrosequencing of bacterial 16S rRNA genes revealed that DNA from the Gram-negative species Ralstonia was most prevalent. Interestingly, fecal abundance of Ralstonia pickettii was increased in obese subjects with pre-diabetes and T2DM. To assess if R. pickettii was causally involved in development of obesity and T2DM, we performed a proof-of-concept study in diet-induced obese (DIO) mice. Compared to vehicle-treated control mice, R. pickettii-treated DIO mice had reduced glucose tolerance. In addition, circulating levels of endotoxin were increased in R. pickettii-treated mice. In conclusion, this study suggests that intestinal Ralstonia is increased in obese human subjects with T2DM and reciprocally worsens glucose tolerance in DIO mice.
Collapse
Affiliation(s)
| | - Petia Kovatcheva-Datchary
- Wallenberg Laboratory, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Guido J. Bakker
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Stefan R. Havik
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Hilde Herrema
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
- * E-mail: (MN); (HH)
| | - Patrice D. Cani
- Université catholique de Louvain, WELBIO (Walloon Excellence in Life sciences and BIOtechnology), Louvain Drug Research Institute, Brussels, Belgium
| | - Kristien E. Bouter
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Clara Belzer
- Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands
| | - Julia J. Witjes
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Anne Vrieze
- Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Noor de Sonnaville
- Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Alice Chaplin
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Daniel H. van Raalte
- Diabetes Center, Department of Internal medicine, VU University Medical Center, Amsterdam, The Netherlands
- ICAR, VU University Medical Center, Amsterdam, The Netherlands
| | - Steven Aalvink
- Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands
| | | | | | - Göran Bergström
- Wallenberg Laboratory, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
| | | | | | - Joost B. L. Hoekstra
- Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Frits Holleman
- Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Erik S. G. Stroes
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Albert K. Groen
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
- Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Fredrik Bäckhed
- Wallenberg Laboratory, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
- Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Metabolic Receptology and Enteroendocrinology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Willem M. de Vos
- Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands
- RPU Immunobiology, University of Helsinki, Helsinki, Finland
| | - Max Nieuwdorp
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
- Wallenberg Laboratory, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
- Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
- Diabetes Center, Department of Internal medicine, VU University Medical Center, Amsterdam, The Netherlands
- ICAR, VU University Medical Center, Amsterdam, The Netherlands
- * E-mail: (MN); (HH)
| |
Collapse
|
4
|
Kootte RS, Levin E, Salojärvi J, Smits LP, Hartstra AV, Udayappan SD, Hermes G, Bouter KE, Koopen AM, Holst JJ, Knop FK, Blaak EE, Zhao J, Smidt H, Harms AC, Hankemeijer T, Bergman JJGHM, Romijn HA, Schaap FG, Olde Damink SWM, Ackermans MT, Dallinga-Thie GM, Zoetendal E, de Vos WM, Serlie MJ, Stroes ESG, Groen AK, Nieuwdorp M. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab 2017; 26:611-619.e6. [PMID: 28978426 DOI: 10.1016/j.cmet.2017.09.008] [Citation(s) in RCA: 577] [Impact Index Per Article: 82.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2017] [Revised: 07/15/2017] [Accepted: 09/14/2017] [Indexed: 12/29/2022]
Abstract
The intestinal microbiota has been implicated in insulin resistance, although evidence regarding causality in humans is scarce. We therefore studied the effect of lean donor (allogenic) versus own (autologous) fecal microbiota transplantation (FMT) to male recipients with the metabolic syndrome. Whereas we did not observe metabolic changes at 18 weeks after FMT, insulin sensitivity at 6 weeks after allogenic FMT was significantly improved, accompanied by altered microbiota composition. We also observed changes in plasma metabolites such as γ-aminobutyric acid and show that metabolic response upon allogenic FMT (defined as improved insulin sensitivity 6 weeks after FMT) is dependent on decreased fecal microbial diversity at baseline. In conclusion, the beneficial effects of lean donor FMT on glucose metabolism are associated with changes in intestinal microbiota and plasma metabolites and can be predicted based on baseline fecal microbiota composition.
Collapse
Affiliation(s)
- Ruud S Kootte
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands; Top Institute of Food and Nutrition, 6700 AN Wageningen, the Netherlands
| | - Evgeni Levin
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands; Horaizon BV, 3062 ME Rotterdam, the Netherlands
| | - Jarkko Salojärvi
- Department of Biosciences, University of Helsinki, 00014 Helsinki, Finland
| | - Loek P Smits
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Annick V Hartstra
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Shanti D Udayappan
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Gerben Hermes
- Top Institute of Food and Nutrition, 6700 AN Wageningen, the Netherlands; Laboratory of Microbiology, Wageningen University, 6703 HB Wageningen, the Netherlands
| | - Kristien E Bouter
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Annefleur M Koopen
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Jens J Holst
- NNF Center for Basic Metabolic Research, Department of Biomedical Sciences, the Panum Institute, University of Copenhagen, 2200 Copenhagen, Denmark
| | - Filip K Knop
- Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
| | - Ellen E Blaak
- Top Institute of Food and Nutrition, 6700 AN Wageningen, the Netherlands; Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6229 ER Maastricht, the Netherlands
| | - Jing Zhao
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Hauke Smidt
- Top Institute of Food and Nutrition, 6700 AN Wageningen, the Netherlands; Laboratory of Microbiology, Wageningen University, 6703 HB Wageningen, the Netherlands
| | - Amy C Harms
- Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands
| | - Thomas Hankemeijer
- Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands
| | - Jacques J G H M Bergman
- Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Hans A Romijn
- Department of Internal Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Frank G Schaap
- Department of Surgery, Maastricht University Medical Center, 6229 ER Maastricht, the Netherlands
| | - Steven W M Olde Damink
- Department of Surgery, Maastricht University Medical Center, 6229 ER Maastricht, the Netherlands
| | - Mariette T Ackermans
- Department of Clinical Chemistry, Laboratory of Endocrinology, Academic Medical Center, 1105 AZ Amsterdam, the Netherlands
| | - Geesje M Dallinga-Thie
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Erwin Zoetendal
- Top Institute of Food and Nutrition, 6700 AN Wageningen, the Netherlands; Laboratory of Microbiology, Wageningen University, 6703 HB Wageningen, the Netherlands
| | - Willem M de Vos
- Laboratory of Microbiology, Wageningen University, 6703 HB Wageningen, the Netherlands; Immunobiology Research Program, Department of Bacteriology and Immunology, University of Helsinki, 00014 Helsinki, Finland
| | - Mireille J Serlie
- Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Erik S G Stroes
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Albert K Groen
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands; Top Institute of Food and Nutrition, 6700 AN Wageningen, the Netherlands
| | - Max Nieuwdorp
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands; Top Institute of Food and Nutrition, 6700 AN Wageningen, the Netherlands; Department of Internal Medicine, VUMC, Free University, Amsterdam, the Netherlands; Wallenberg Laboratory, Sahlgrenska Hospital, University of Gothenburg, Gothenburg, Sweden.
| |
Collapse
|
5
|
Bouter KE, van Raalte DH, Groen AK, Nieuwdorp M. Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction. Gastroenterology 2017; 152:1671-1678. [PMID: 28192102 DOI: 10.1053/j.gastro.2016.12.048] [Citation(s) in RCA: 266] [Impact Index Per Article: 38.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Revised: 12/29/2016] [Accepted: 12/30/2016] [Indexed: 02/08/2023]
Abstract
The potential role of intestinal microbiota in the etiology of various human diseases has attracted massive attention in the last decade. As such, the intestinal microbiota has been advanced as an important contributor in the development of obesity and obesity-related metabolic dysfunctions, amongst others. Experiments in animal models have produced evidence for a causal role of intestinal microbiota in the etiology of obesity and insulin resistance. However, with a few exceptions, such causal relation is lacking for humans and most publications merely report associations between intestinal microbial composition and metabolic disorders such as obesity and type 2 diabetes. Thus, the reciprocal relationship between the bacteria and these metabolic disorders remains a matter of debate. The main objective of this review is to critically assess the driving role of intestinal microbe composition in the etiology, prevention, and treatment of obesity and obesity-related metabolic dysfunction, including type 2 diabetes.
Collapse
Affiliation(s)
- Kristien E Bouter
- Department of Vascular Medicine, Academic Medical Center (AMC), University of Amsterdam, The Netherlands
| | - Daniël H van Raalte
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands; Institute for Cardiovascular Research (ICaR), VU University Medical Center, Amsterdam, The Netherlands
| | - Albert K Groen
- Department of Vascular Medicine, Academic Medical Center (AMC), University of Amsterdam, The Netherlands; Department of Pediatrics, Laboratory of Metabolic Diseases, University of Groningen, UMCG, Groningen, The Netherlands
| | - Max Nieuwdorp
- Department of Vascular Medicine, Academic Medical Center (AMC), University of Amsterdam, The Netherlands; Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands; Institute for Cardiovascular Research (ICaR), VU University Medical Center, Amsterdam, The Netherlands; Wallenberg Laboratory, University of Gothenberg, Gothenberg, Sweden.
| |
Collapse
|